xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

709

Orlandi et al.

1655. Di Capite J, Nelson C, Bates G, Parekh AB. Targeting Ca2 + release-activated Ca2 + channel channels and leukotriene receptors provides a novel combination strategy for treat ing nasal polyposis. J Allergy Clin Immunol . 2009;124(5):1014 1021.e1011-e1013. 1656. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med . 1998;157(4 Pt 1):1187-1194. 1657. Van Gerven L, Langdon C, Cordero A, Cardelus S, Mullol J, Alobid I. Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps. Laryngoscope . 2018;128(8):1743-1751. 1658. Stryjewska-Makuch G, Humeniuk-Arasiewicz M, Jura Szoltys E, Gluck J. the effect of antileukotrienes on the results of postoperative treatment of paranasal sinuses in patients with non-steroidal anti-inflammatory drug-exacerbated respi ratory disease. Int Arch Allergy Immunol . 2019;179(4):281-289. 1659. Yelverton JC, Holmes TW, Johnson CM, Gelves CR, Koun takis SE. Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis. Int Forum Allergy Rhinol . 2016;6(3):243-247. 1660. Schwartz HJ, Petty T, Dube LM, Swanson LJ, Lancaster JF. A randomized controlled trial comparing zileuton with theo phylline in moderate asthma. The Zileuton Study Group. Arch InternMed . 1998;158(2):141-148. 1661. Ferrara A, Stortini G, Bellussi L, Di Girolamo S, Zuccarini N, Passali D. Furosemide long-term inhalation therapy in patients with nasal polyposis. Acta Otorhinolaryngol Ital . 1994;14(6):633-642. 1662. Passali D, Bellussi L, Lauriello M, Ferrara A. Can the recur rence of nasal polyposis be prevented? A new therapeutic approach. Acta Otorhinolaryngol Ital . 1995;15(2):91-100. 1663. Passàli D, Mezzedimi C, Passàli GC, Bellussi L. Efficacy of inhalation form of furosemide to prevent postsurgical relapses of rhinosinusal polyposis. ORL J Otorhinolaryngol Relat Spec . 2000;62(6):307-310. 1664. Hashemian F, Ghorbanian MA, Hashemian F, et al. Effect of topical furosemide on rhinosinusal polyposis relapse after endoscopic sinus surgery: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg . 2016;142(11):1045-1049. 1665. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: developing guidance for clinical trials. Otolaryngol Head Neck Surg . 2006;135(5 Suppl):S31-80. 1666. Kroflic B, Coer A, Baudoin T, Kalogjera L. Topical furosemide versus oral steroid in preoperative management of nasal poly posis. Eur Arch Otorhinolaryngol . 2006;263(8):767-771. 1667. Bosso JV, Locke TB, Kuan EC, et al. Complete endoscopic sinus surgery followed by aspirin desensitization is associated with decreased overall corticosteroid use. Int Forum Allergy Rhinol . 2020;10(9):1043-1048. 1668. Lumry WR, Curd JG, Zeiger RS, Pleskow WW, Stevenson DD. Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration. J Allergy Clin Immunol . 1983;71(6):580-587. 1669. Gosepath J, Schaefer D, Amedee RG, Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head NeckSurg . 2001;127(3):316-321.

administration for chronic sinusitis. Rhinology . 2009;47(1):66 71. 1640. Katsuta S, Osafune H, Takita R, Sugamata M. Therapeutic effect of roxithromycin on chronic sinusitis with nasal – polyps clinical, computed tomography, and electron microscopy analysis. Nihon Jibiinkoka Gakkai Kaiho . 2002;105(12):1189 1197. 1641. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. AmJRhinol . 2000;14(3):143-148. 1642. Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhi nology . 2018;56(1):42-45. 1643. Mostafa BE, Fadel M, Mohammed MA, Hamdi TAH, Ask oura AM. Omalizumab versus intranasal steroids in the post operative management of patients with allergic fungal rhinos inusitis. Eur Arch Otorhinolaryngol . 2020;277(1):121-128. 1644. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol . 2011;128(5):989 995.e981-988. 1645. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol . 2020;146(3):595-605. 1646. Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9 α ,11 β -prostaglandin F2 overpro duction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol . 2016;137(5):1585-1587.e1584. 1647. Wentzel JL, Soler ZM, DeYoung K, Nguyen SA, Lohia S, Schlosser RJ. Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review. Am J Rhinol Allergy . 2013;27(6):482-489. 1648. Smith TL, Sautter NB. Is montelukast indicated for treat ment of chronic rhinosinusitis with polyposis? Laryngoscope . 2014;124(8):1735-1736. 1649. Schaper C, Noga O, Koch B, et al. Anti-inflammatory prop erties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol . 2011;21(1):51-58. 1650. Pauli C, Fintelmann R, Klemens C, et al. Polyposis nasi– improvement in quality of life by the influence of leukotrien receptor antagonists. Laryngorhinootologie . 2007;86(4):282 286. 1651. Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M. Role of leukotriene inhibitors in the postoperative manage ment of nasal polyps. ORL J Otorhinolaryngol Relat Spec . 2005;67(3):148-153. 1652. Vuralkan E, Saka C, Akin I, et al. Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps. Ther Adv Respir Dis . 2012;6(1):5-10. 1653. Stewart RA, Ram B, Hamilton G, Weiner J, Kane KJ. Mon telukast as an adjunct to oral and inhaled steroid ther apy in chronic nasal polyposis. Otolaryngol Head Neck Surg . 2008;139(5):682-687. 1654. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy . 2001;31(9):1385-1391.